Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

80.70 +0.39 (+0.48%)
Streaming Delayed Price Updated: 3:02 PM EDT, Jun 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
54 55 Next >
Novo Nordisk's Diabetes, Weight Loss Drugs Under UK Scrutiny: Follows Suicidal Behavior Reports
The Medicines and Healthcare Products Regulatory Agency (MHRA), the U.K.'s drug regulatory authority, is reportedly scrutinizing a category of drugs used in diabetes medication and a weight loss... 
Via Benzinga
Argenx Stock Rides 'Megabuster' Drug Excitement To 40% Gain Before Earnings
Argenx is up around 40% in 2023 after shares soared nearly 30% in a single day last week. 
Via Investor's Business Daily
Dow Jones Leads Weekly Gains As Tesla, Netflix Sell-Offs Dent Nasdaq; Big Banks Show Resilience To Volatility
Via Benzinga
This Is What Whales Are Betting On AstraZeneca
Via Benzinga
A Look Into AstraZeneca's Debt
Via Benzinga
AstraZeneca Unusual Options Activity
Via Benzinga
AstraZeneca Plummets, Sacrificing A Breakout, On Mixed Results In Lung Cancer Treatment
The company tested a treatment in combination with Daiichi Sankyo. 
Via Investor's Business Daily
Why Pieris Pharmaceuticals Shares Shooting Higher Today?
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) shares are trading higher after the company  
Via Benzinga
NBCUniversal's Peacock Raises Prices First Time Since Launch, Warren Buffett Sells Majority of Activision Blizzard Stake Before Microsoft Deal Approval, Novartis Launches $15B Share Buyback: Today's Top Stories
Wall Street Journal 
Via Benzinga
AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants
The FDA approved AstraZeneca Plc (NASDAQ: 
Via Benzinga
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 to 2030. 
Via Benzinga
AstraZeneca Unusual Options Activity For June 28
Via Benzinga
Price Over Earnings Overview: AstraZeneca
Via Benzinga
3 Doomed Biotech Stocks Destined for Disaster
Doomed biotech stocks are a major part of the natural cycle within the sector that results in a lot of failures. 
Via InvestorPlace
The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?
An overweight world is hungry for new treatments. For now, two companies own the market. 
Via Investor's Business Daily
These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
50% Of Women Have Elevated Breast Density, Which Significantly Decreases The Effectiveness Of Mammography – Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis
One in eight women will be diagnosed with breast cancer during 
Via Benzinga
What's Going On With Novavax (NVAX) Stock?
Novavax, Inc. (NASDAQ: NVAX) shares are trading higher on Monday after the company announced an amendment to its Canada supply agreement, under which the Government of Canada will pay Novavax $349.6... 
Via Benzinga
Stock Market Rally Pulls Back As Yields Jump; Tesla, Meta In Focus: Weekly Review
Automakers rallied on sales while Meta's Threads had a big launch. 
Via Investor's Business Daily
Biotech Blues: Stay Balanced Through July Earnings Season
Life Science stocks lack momentum so be prepared for rebalancing and rotation shifts. 
Via Talk Markets
These Were Monday's 2 Stock Movers That Investors Cared About the Most
On a quiet day on Wall Street, a couple of stocks still saw a considerable amount of activity. 
Via The Motley Fool
AstraZeneca Losses Leave The FTSE In The Red To Start July
Despite reaching record highs earlier this year, the UK's FTSE 100 experienced a decline in the April-June period due to volatile commodity prices and persistent inflation concerns. 
Via Talk Markets
AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares... 
Via Benzinga
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial
From AstraZeneca
Via Business Wire
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung... 
Via Benzinga
4 Unparalleled Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Bargains abound with the innovation-driven Nasdaq Composite still well below its all-time high. 
Via The Motley Fool
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)... 
Via Benzinga
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trial
From AstraZeneca
Via Business Wire
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
From AstraZeneca
Via Business Wire
Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead
After a huge run-up in stocks since January investors have come to realize that most of the gains have come from the so-called “Magnificent Seven” tech stocks. 
Via Talk Markets
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
54 55 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.